The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.

Approval Status:

Approved February 1998

Specific Treatments:

inflammation of the cornea due to herpes simplex virus

General Information

Viroptic Oththalmic Solution (trifluridine) 1% has been approved for use in children (ages 6+) as a treatment for inflammation of the cornea caused by the herpes simplex virus. The antiviral agent was previously approved for use in adults.